Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
Policy / Pricing The next FDA commissioner must be a champion for gene therapies pharminent June 5, 2026
Clinical Data Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data pharminent June 5, 2026
Policy / Pricing Stakeholders want Makary’s voucher program paused, call for FDA independence pharminent June 5, 2026
Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? pharminent June 5, 2026
Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA pharminent June 5, 2026
M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity pharminent June 4, 2026
M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership pharminent June 4, 2026
Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy pharminent June 4, 2026
Clinical Data Legend surges on early data for ‘in vivo’ lymphoma cell therapy pharminent June 3, 2026
M&A / Deals Travere beefs up rare kidney disease portfolio with up to $1.1B China deal pharminent June 3, 2026
Regulatory FDA taps prior knowledge to expedite cell and gene therapy development pharminent June 3, 2026
M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026
Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026
Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026
Clinical Data ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off pharminent June 2, 2026
Clinical Data AbiVax falls as safety worries cloud ‘landmark’ immune drug results pharminent June 2, 2026
M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments pharminent June 2, 2026
Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs pharminent June 2, 2026
Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026
